=>
Uploading C:\Program Files\Stnexp\Queries\10-728244.str



chain nodes :
13 15 16 18 20 22 24 25 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
3-18 5-15 6-13 7-24 8-22 9-20 10-13 11-28 12-25 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
3-18 6-13 7-24 8-22 9-20 10-13 11-28 12-25
exact bonds :
5-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:CH3,Et

G2:Cl,F

G3:H,F

G4:H,Cl,F,CH3,Et,OH,MeO,EtO

G5:Cl,F,CH3,CF3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 18:CLASS 20:CLASS 22:CLASS
24:CLASS 25:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d

```
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 ful
FULL SEARCH INITIATED 18:22:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    145 TO ITERATE

100.0% PROCESSED      145 ITERATIONS                          32 ANSWERS
SEARCH TIME: 00.00.01

L2           32 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 161.33     161.54

FILE 'CAPLUS' ENTERED AT 18:22:41 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 Sep 2005  VOL 143 ISS 10
FILE LAST UPDATED: 31 Aug 2005  (20050831/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l2
L3          196 L2

=> d ibib abs hitstr 20-30
```

L3 ANSWER 20 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:409223 CAPLUS
DOCUMENT NUMBER: 142:441891
TITLE: Method and compositions for the treatment and prevention of pain and inflammation with cyclooxygenase-2 inhibitors and polyunsaturated fatty acids
INVENTOR(S): Pulaski, Steven P.; Kundel, Susan
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of U.S. Ser. No. 215,539.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101563	A1	20050512	US 2004-783160	20040219
US 2003114416	A1	20030619	US 2002-215539	20020809
PRIORITY APPLN. INFO.:			US 2001-312211P	P 20010814
			US 2002-215539	A2 20020809

AB A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsatd. fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsatd. fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compns. that contain the combination of Cox-2 inhibitor and polyunsatd. fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compns.
IT 220991-20-8, Lumiracoxib
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as COX-2 selective inhibitor; cyclooxygenase-2 inhibitor and polyunsatd. fatty acid combination for treatment and prevention of pain and inflammation)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 21 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:405379 CAPLUS
DOCUMENT NUMBER: 142:441853
TITLE: HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia
INVENTOR(S): Masferrer, Jaime L.; Penning, Thomas D.; Wang, Xing; Heuvelman, Deborah M.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041879	A2	20050512	WO 2004-US35949	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-515021P	P 20031028

OTHER SOURCE(S): MARPAT 142:441853
AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising an HSP90 inhibitor and a phosphodiesterase inhibitor, and optionally a COX-2 inhibitor. Preparation of, e.g. 4-[2-(4-fluorophenyl)phenyl]benzenesulfonamide, is described.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 22 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:405366 CAPLUS
DOCUMENT NUMBER: 142:441879
TITLE: Method and compositions for the treatment or prevention of respiratory inflammation using a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor
INVENTOR(S): Smith, Walter G.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041864	A2	20050512	WO 2004-US34685	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005187278	A1	20050825	US 2004-927198	20040826
PRIORITY APPLN. INFO.:			US 2003-513099P	P 20031021
			US 2003-498529P	P 20030828

AB A method is described for the prevention and/or treatment of respiratory inflammation, and in particular asthma and COPD, in a subject in need of such prevention or treatment, the method comprising administering to the subject a cyclooxygenase 2 inhibitor in combination with a phosphodiesterase 4 inhibitor. Also described are therapeutic and pharmaceutical compns. and kits that are useful in the invention. Preparation of celecoxib and of roflumilast is described, as is the production of a composition containing these two compds.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX2 inhibitor-PDE4 inhibitor combination for treatment and prevention of respiratory inflammation)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 23 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:395085 CAPLUS
DOCUMENT NUMBER: 142:423900
TITLE: Combinations of cyclooxygenase (COX) inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea
INVENTOR(S): Barker, Laura Daisy; Russell, Rachel Jane; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039565	A1	20050506	WO 2004-IB3386	20041014

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-25021 A 20031027

AB The invention describes the use of a combination of (A) a vasopressin receptor family antagonist, or a pharmaceutically acceptable derivative thereof; and (B) a COX inhibitor, or a pharmaceutically acceptable derivative thereof, for the treatment or prophylaxis of dysmenorrhea. Preparation of celecoxib is also described.

IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase inhibitor-vasopressin receptor antagonist combination for treatment of dysmenorrhea)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 23 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:387611 CAPLUS
DOCUMENT NUMBER: 143:38313
TITLE: Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production
AUTHOR(S): Kukar, Thomas; Murphy, Michael Paul; Eriksen, Jason L.; Sagi, Sarah A.; Weggen, Sascha; Smith, Tawnya E.; Ladd, Thomas; Khan, Murad A.; Kache, Rajashaker; Beard, Jenny; Dodson, Mark; Merit, Sami; Ozols, Victor V.; Anastasiadis, Panos Z.; Das, Pritam; Fauq, Abdul; Koo, Edward H.; Golde, Todd E.
CORPORATE SOURCE: Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, FL, 32224, USA
SOURCE: Nature Medicine (New York, NY, United States) (2005), 11(5), 545-550
CODEN: NAMEFI; ISSN: 1078-8956
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Increased Aβ42 production has been linked to the development of Alzheimer disease. We now identify a number of compds. that raise Aβ42. Among the more potent Aβ42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Aβ42, including multiple COX-2-selective derivs. of two Aβ42-lowering NSAIDs. Compds. devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Aβ42. These compds. seem to target the γ-secretase complex, increasing γ-secretase-catalyzed production of Aβ42 in vitro. Short-term in vivo studies show that two Aβ42-raising compds. increase Aβ42 levels in the brains of mice. The elevations in Aβ42 by these compds. are comparable to the increases in Aβ42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid β protein precursor and presenilins, raising the possibility that exogenous compds. or naturally occurring isoprenoids might increase Aβ42 production in humans.

IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(diverse compds. mimic Alzheimer disease-causing mutations by augmenting Aβ42 production)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 25 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:387241 CAPLUS
DOCUMENT NUMBER: 142:476023
TITLE: Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib
AUTHOR(S): Lozano-Cuenca, Jair; Castaneda-Hernandez, Gilberto; Granados-Soto, Vinicio
CORPORATE SOURCE: Departamento de Farmacobiologia, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City, 14330, Mex.
SOURCE: European Journal of Pharmacology (2005), 513(1-2), 81-91
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The possible participation of the nitric oxide (NO)-cGMP-K+ channel pathway, serotonergic or opioidergic system on lumiracoxib-induced local or intrathecal antinociception was assessed in the formalin test. Local or intrathecal administration of lumiracoxib dose-dependently produced antinociception in the second phase of the test. Moreover, local or intrathecal pretreatment with N G-L-nitro-arginine Me ester (L-NAME, NO synthesis inhibitor), 1H-(1,2,4)-oxadiazolo(4,2-a)quinoxalin-1-one (ODQ, guanylyl cyclase inhibitor), glibenclamide (ATP-sensitive K+ channel blocker), charybdotoxin and apamin (large- and small-conductance Ca2+-activated-K+ channel blockers, resp.) or margatoxin (voltage-dependent K+ channel blocker), but not NG-D-nitro-arginine Me ester (D-NAME) or vehicle, significantly prevented lumiracoxib-induced antinociception. The intrathecal injection of methiothepin (serotonin receptor antagonist) reduced lumiracoxib-induced intrathecal antinociception. Local peripheral or intrathecal naloxone did not modify either local or intrathecal lumiracoxib-induced antinociception. Results suggest that lumiracoxib activates the NO-cGMP-K+ channels to produce local and intrathecal antinociception. Data also suggest that lumiracoxib
activates the intrathecal serotonergic system, but not opioid receptors either at peripheral or spinal sites.
IT 220991-20-8, Lumiracoxib
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peripheral and spinal mechanisms of antinociceptive action of lumiracoxib)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS

L3 ANSWER 25 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 26 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:369270 CAPLUS
DOCUMENT NUMBER: 142:417201
TITLE: Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
INVENTOR(S): Dannenfelser, Rose-marie; Georgousis, Vivian Christine; Khaled, Maha Y.; Patel, Tarun S.; Sikora, Joseph; Wang, Barbara
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037266	A1	20050428	WO 2004-EP11223	20041007

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-509459P P 20031008

AB The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal in need of such treatment by parenteral administration of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof. For example, a parenteral solution contained potassium
5-methyl-2-(2'-chloro-
6'-fluoroanilino)phenylacetate 45.2 mg, polyethylene glycol 400 400 mg, Polysorbate 80 20 mg, monothioglycerol 2.0 mg, glycine 7.5 mg, water to 1 mL, and sodium hydroxide as needed to pH 9.0.
IT 220991-20-8 850402-49-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(parenteral solution containing
methyl(chlorofluoroanilino)phenylacetic acid)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 26 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 850402-49-2 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, monopotassium salt (9CI) (CA INDEX NAME)



● K

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 27 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 27 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:369225 CAPLUS
DOCUMENT NUMBER: 142:404248
TITLE: Tetrasubstituted pyrimidopyrimidines, alone or in combination with other agents, for the treatment of immunoinflammatory disorders
INVENTOR(S): Keith, Curtis; Borisy, Alexis; Zimmermann, Grant R.; Jost-Price, Edward Roydon; Manivasakam, Palaniyandi; Hurst, Nicole; Poley, Michael A.; Slavonic, Michael S.; Smith, Brendan; Auspitz, Benjamin A.
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037203	A2	20050428	WO 2004-US33656	20041013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005119160	A1	20050602	US 2004-966228	20041015
PRIORITY APPLN. INFO.:			US 2003-512415P	P 20031015

AB The invention discloses a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetrasubstituted pyrimidopyrimidine, either alone or in combination with one or more addnl. agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more addnl. agents.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidopyrimidine tetrasubstituted derivs., alone or in combination with other agents, for treatment of immunoinflammatory disorders)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:369219 CAPLUS
DOCUMENT NUMBER: 142:386018
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic-mediated central nervous system disorders or injury
INVENTOR(S): Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037193	A2	20050428	WO 2004-US32515	20041004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005113434	A1	20050526	US 2004-958145	20041004
PRIORITY APPLN. INFO.:			US 2003-508638P	P 20031003

AB Methods and compns. for the treatment of reduced blood flow to the central nervous system are provided. The method comprises administering to a subject a composition having a cyclooxygenase-2 selective inhibitor in combination with applying hypothermic conditions to the subject to provide improved neurol. function in subjects with ischemic-mediated central nervous system damage including stroke, traumatic brain and spinal cord injury.
IT 220991-20-8, Lumiracoxib
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as COX-2 selective inhibitor; cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for treatment of ischemic-mediated central nervous system disorders or injury)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 29 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:366496 CAPLUS
DOCUMENT NUMBER: 143:126197
TITLE: Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model
AUTHOR(S): Esser, Ronald E.; Miserendino-Molteni, Rocca; Sharr, Michele; Zhang, Xiaoli; Porter, Wilma; Ramos, Luis; Cramer, Jeffrey A.; Zhuang, Shumin; Georgieva, Anna; Maniara, Wieslawa
CORPORATE SOURCE: Arthritis and Bone Metabolism, Novartis Institutes for BioMedical Research, Novartis Pharmaceuticals Corp., East Hanover, NJ, 07936, USA
SOURCE: European Journal of Pharmaceutical Sciences (2005), 25(1), 25-30
CODEN: EPSCED; ISSN: 0928-0987
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Purpose: To investigate the pharmacodynamic behavior of the selective cyclooxygenase-2 inhibitor, lumiracoxib, in the rat air pouch. Air pouches were injected with lipopolysaccharide to stimulate prostaglandin E2 (PGE2) production 1 h after lumiracoxib treatment. Pouch fluid samples were collected 6 or 24 h after lumiracoxib administration to measure PGE2 levels. Lumiracoxib concns. in pouch fluid and plasma were measured by mass spectrometry. Oral administration of lumiracoxib resulted in dose-dependent inhibition of PGE2 production 6 and 24 h post-dose. The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, resp. Lumiracoxib concns. in plasma and pouch fluid increased in proportion to dose. There was a strong pos. correlation between lumiracoxib concns. in plasma and pouch fluid compartments. Lumiracoxib concns. were higher in plasma than in pouch fluid 6 h post-dose, but at 24 h post-dose, pouch fluid concns. were ≥4-fold greater than plasma concns. Lumiracoxib readily enters the air pouch and persists in this extravascular compartment for a longer period of time than in plasma. This distribution profile may contribute to the ability of lumiracoxib to inhibit PGE2 production up to 24 h after dosing.

IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacodynamic behavior of selective cyclooxygenase-2 inhibitor lumiracoxib in lipopolysaccharide-stimulated rat air pouch model)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:300267 CAPLUS
DOCUMENT NUMBER: 142:349032
TITLE: Nitrosylated analgesic and/or antiinflammatory drugs having antiviral activity
INVENTOR(S): Bolla, Manlio; Santus, Giancarlo; De Soldato, Piero
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030224	A1	20050407	WO 2004-EP51551	20040720

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-292378 A 20030926

OTHER SOURCE(S): MARPAT 142:349032

AB The invention discloses the use of nitrosylated analgesic and/or antiinflammatory drugs for the prevention and/or treatment of viral diseases and/or their complications.

IT 220991-20-8D, COX-189, nitrosylated derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosylated analgesic and/or antiinflammatory drugs having antiviral activity)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 50-60

L3 ANSWER 50 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:136975 CAPLUS
DOCUMENT NUMBER: 142:456537
TITLE: Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis
AUTHOR(S): Geusens, P.; Alten, R.; Rovensky, J.; Sloan, V. S.; Krammer, G.; Kralidis, G.; Richardson, P.
CORPORATE SOURCE: Biomedisch Onderzoeksinstituut, Limburgs Universitair Centrum, Diepenbeek, Belg.
SOURCE: International Journal of Clinical Practice (2004), 58(11), 1033-1041
CODEN: IJCPF9; ISSN: 1368-5031
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A randomized, double-blind study was performed to assess the efficacy and tolerability of lumiracoxib in patients with rheumatoid arthritis (RA). Patients received lumiracoxib 200 mg once daily (o.d.) (n = 280), lumiracoxib 400 mg o.d. (n = 281), naproxen 500 mg twice daily (n = 279) or placebo (n = 284) for 26 wk. The primary efficacy variable was response to treatment according to ACR20 criteria (adjusted for prohibited concomitant or excessive rescue medication use and discontinuations due to unsatisfactory therapeutic response) at week 13. Safety and tolerability was also assessed. Significantly more patients receiving lumiracoxib than placebo were responders according to ACR20 criteria at week 13 (41.1 and 42.7% for lumiracoxib 200 and 400 mg o.d., resp.; 32.4% for placebo; both $p<0.05$). The proportion responding to naproxen (39.1%) was not significantly different from placebo. Prespecified gastrointestinal adverse events were more frequent with naproxen than with either lumiracoxib dose or placebo. Lumiracoxib is therefore an effective and well-tolerated therapy for RA.

IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lumiracoxib efficacy, safety, and tolerability vs. naproxen in patients with rheumatoid arthritis)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 50 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 51 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:99310 CAPLUS
DOCUMENT NUMBER: 142:191297
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
INVENTOR(S): Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009354	A2	20050203	WO 2004-US22692	20040715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005075341	A1	20050407	US 2004-891913	20040715
PRIORITY APPLN. INFO.:			US 2003-488211P	P 20030717

OTHER SOURCE(S): MARPAT 142:191297

AB The present invention provides compns. and methods for the treatment of ischemic-mediated central nervous system disorders or injuries. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic-mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor.

IT 220991-20-8, Lumiracoxib 220991-33-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for treatment of ischemic-mediated central nervous system disorders or injury)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 51 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 52 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:99157 CAPLUS
DOCUMENT NUMBER: 142:170033
TITLE: Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
INVENTOR(S): Maziasz, Timothy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 172 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026902	A1	20050203	US 2004-769485	20040130
PRIORITY APPLN. INFO.:			US 2003-443910P P	20030131

OTHER SOURCE(S): MARPAT 142:170033
AB The present invention provides compns. and methods for the treatment of human immunodeficiency virus (HIV) infection as well as HIV associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.
IT 220991-20-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 53 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 53 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:76261 CAPLUS
DOCUMENT NUMBER: 142:148813
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
INVENTOR(S): Stephenson, Diane T.; Taylor, Duncan P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007156	A1	20050127	WO 2004-US22190	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080083	A1	20050414	US 2004-886904	20040708
PRIORITY APPLN. INFO.:			US 2003-486775P P	20030710

OTHER SOURCE(S): MARPAT 142:148813
AB The present invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of an angiotensin II receptor antagonist in combination with a cyclooxygenase-2 selective inhibitor. Examples include evaluation of COX-1 and COX-2 activity in vitro, measuring platelet aggregation and platelet activation markers, and global cerebral ischemia.
IT 220991-20-8, Lumiracoxib 220991-33-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of CNS damage)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 54 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:76247 CAPLUS
DOCUMENT NUMBER: 142:148812
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and a non-NMDA glutamate modulator for the treatment of central nervous system damage
INVENTOR(S): Stephenson, Diane T.; Taylor, Duncan P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007106	A2	20050127	WO 2004-US22189	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005101597	A1	20050512	US 2004-887035	20040708
PRIORITY APPLN. INFO.:			US 2003-486654P P	20030710

OTHER SOURCE(S): MARPAT 142:148812
AB The invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a non-NMDA glutamate modulator in combination with a cyclooxygenase-2 selective inhibitor.
IT 220991-20-8, Lumiracoxib 220991-20-8D, Lumiracoxib, prodrug derivs. and esters 220991-33-3 220991-33-3D, prodrug derivs. and esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 selective inhibitor combination with non-NMDA glutamate modulator for treatment of central nervous system damage)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 54 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 55 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 55 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:68065 CAPLUS
DOCUMENT NUMBER: 143:19038
TITLE: Efficacy of lumiracoxib in osteoarthritis: a review of nine studies
AUTHOR(S): Berenbaum, F.; Grifka, J.; Brown, J. P.; Zacher, J.; Moore, A.; Krammer, G.; Dutta, D.; Sloan, V. S.
CORPORATE SOURCE: Pierre and Marie Curie University-Saint-Antoine Hospital, Paris, Fr.
SOURCE: Journal of International Medical Research (2005), 33(1), 21-41
CODEN: JIMRBV; ISSN: 0300-0605
PUBLISHER: Cambridge Medical Publications Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Lumiracoxib is a cyclooxygenase-2 selective inhibitor in development for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute pain. We reviewed nine clin. studies of 1 - 52 wk' duration demonstrating the efficacy of lumiracoxib in OA. Male and female patients aged ≥ 18 years with primary OA of the hand, hip or knee received lumiracoxib, placebo or active comparators (diclofenac, celecoxib or rofecoxib). Lumiracoxib provided consistent redns. in OA pain intensity and improvements in the patient's global assessment of disease activity and functional status (assessed using the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire or the Australian/Canadian OA Hand Index). These results were superior to placebo and similar to the active comparators tested. In addition, lumiracoxib was consistently superior to placebo and generally similar to active comparators in terms of the new Outcome Measures in Clin. Trials and Osteoarthritis Research Society International criteria. These were used to provide a single measure of response to treatment, taking into account pain, the patient's global assessment of disease activity and functional status.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lumiracoxib reduced osteoarthritis pain intensity and improved disease activity and functional status and showed similar effect as that of comparators diclofenac, celecoxib, rofecoxib in osteoarthritis patient)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 56 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:59969 CAPLUS
DOCUMENT NUMBER: 142:148822
TITLE: Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
INVENTOR(S): Pulaski, Steven P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 68 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005014729	A1	20050120	US 2004-860307	20040603
WO 2005009342	A2	20050203	WO 2004-US17530	20040603
WO 2005009342	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-487844P P 20030716

AB A method for preventing or treating dermatol. disorders and dermatol. disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatol. treatment agent. Also described are therapeutic compns. comprising a Cox-2 inhibitor and a dermatol. treatment agent. Pharmaceutical compns. and kits for implementing the present method are also described. The COX-2 inhibitor is celecoxib (preparation given).
IT 220991-20-8, Lumiracoxib
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as COX-2 selective inhibitor; cyclooxygenase-2 inhibitor alone and in combination with dermatol. treatment agents for treatment or prevention of dermatol. disorders)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 56 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 57 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:55023 CAPLUS
DOCUMENT NUMBER: 142:127581
TITLE: Combination therapy with DMARD and COX-2 selective inhibitor for treating chronic inflammatory diseases
INVENTOR(S): Rodger, Ian W.; Mazel, Sidney
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004806	A2	20050120	WO 2004-US20715	20040628
WO 2005004806	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-484499P P 20030702

AB The present inventions is directed to a novel DMARD sparing method for treating chronic inflammatory diseases or conditions, such as rheumatoid arthritis, comprising the short-term administration of a disease modifying anti-rheumatic drug (DMARD) followed by reduction of the DMARD and co-administration of a cyclooxygenase-2 selective inhibitor or cessation of the DMARD and continued maintenance therapy using a COX-2 selective inhibitor alone. The present invention provides for an effective DMARD sparing therapy in patients suffering from inflammatory diseases or conditions.

IT 220991-20-8, Lumiracoxib
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as COX-2 selective inhibitor; combination therapy with DMARD and COX-2 selective inhibitor for treating chronic inflammatory diseases)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 57 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 58 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:36561 CAPLUS
DOCUMENT NUMBER: 142:120567
TITLE: Dispersible pharmaceutical compositions for treatment of mastitis and otic disorders
INVENTOR(S): Britten, Nancy Jean; Waldron, Niki Ann; Watts, Jeffrey L.; Hallberg, John Walter; Burns, John W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 795,191.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005009931	A1	20050113	US 2004-903662	20040730
US 2004214753	A1	20041028	US 2004-795191	20040305
WO 2005009472	A2	20050203	WO 2004-IB2474	20040719
WO 2005009472	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-456201P P 20030320
US 2003-492178P P 20030731
US 2004-795191 A2 20040305

AB A method is provided for the treatment and/or prevention of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and to a process for preparing such a composition Thus, a suspension for intramammary infusions contained ceftiofur-HCl 12.5, Labrafil M-1944CS 50, and microcryst. wax 70 mg/mL and cottonseed oil qs.

IT 220991-20-8, Lumiracoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible pharmaceutical compns. for treatment of mastitis and otic disorders)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 58 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 59 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:29184 CAPLUS
DOCUMENT NUMBER: 142:141232
TITLE: Pharmaceutical compositions including an ether and selective COX-2 inhibitor and uses thereof
INVENTOR(S): Kowala, Mark Charles
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002557	A1	20050113	WO 2004-IB2100	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004048910	A1	20040311	US 2003-639719	20030812
US 2005004196	A1	20050106	US 2004-884891	20040702

PRIORITY APPLN. INFO.: US 2003-484808P P 20030703
US 2002-405250P P 20020822
US 2003-475443P P 20030603
US 2003-477092P P 20030609

OTHER SOURCE(S): MARPAT 142:141232
AB Disclosed herein are pharmaceutical compns. including a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of said dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl, and a selective cyclooxygenase-2 (COX-2) inhibitor, or a pharmaceutically acceptable salt of said selective COX-2 inhibitor. Also disclosed are methods of using such pharmaceutical compns. for the treatment of inflammation and inflammation-associated diseases, inflammation and inflammation-associated disorders mediated by proinflammatory cytokines, and proinflammatory cytokine induced CRP production For example, an injection containing CI-1027 and Vioxx (rofecoxib) can effectively treat the inflammation in rat arthritis model.
IT 220991-20-8, Lumiracoxib

L3 ANSWER 59 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory compns. contg. dialkyl ethers in combination with COX-2 inhibitors)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 60 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:17015 CAPLUS
DOCUMENT NUMBER: 142:120515
TITLE: Dispersible formulations containing anti-inflammatory agents and other active ingredients for infusion
INVENTOR(S): Britten, Nancy Jean; Waldron, Niki Ann; Watts, Jeffrey L.; Hallberg, John Walter; Burns, John W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 803,146.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005004098	A1	20050106	US 2004-909050	20040730
US 2004235803	A1	20041125	US 2004-803146	20040317
WO 2005009436	A1	20050203	WO 2004-IB2461	20040719
WO 2005009436	C1	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-456325P P 20030320
US 2003-492121P P 20030731
US 2004-803146 A2 20040317

OTHER SOURCE(S): MARPAT 142:120515
AB A method is provided for treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and a process for preparing such a composition For example, a suspension to be administered by intramammary infusion was prepared containing parecoxib 100 mg/mL, Labrafil M-1944CS 50 mg/mL, microcryst. wax 70 mg/mL., and cottonseed oil q.s.
IT 220991-20-8, Lumiracoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible formulation containing anti-inflammatory agents and other active ingredients for infusion)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 60 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



=> d ibib abs hitstr 100-110

L3 ANSWER 100 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:679661 CAPLUS
DOCUMENT NUMBER: 141:254054
TITLE: Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics
AUTHOR(S): Hawkey, C. J.; Farkouh, M.; Gitton, X.; Ehrsam, E.; Huels, J.; Richardson, P.
CORPORATE SOURCE: University Hospital, Nottingham, UK
SOURCE: Alimentary Pharmacology and Therapeutics (2004), 20(1), 51-63
CODEN: APTHEN; ISSN: 0269-2813
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background: Cyclooxygenase-2 selective inhibitors were developed to reduce the incidence of life-threatening gastrointestinal ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs. Previous outcomes studies have, variously, lacked power to investigate this endpoint, focused on broader outcomes, or been too small to quantify the influence of aspirin. Aim: To evaluate lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, vs. non-selective non-steroidal anti-inflammatory drugs in an outcomes study of considerably increased size. This paper describes the study's methodol. Methods and patients: The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double-blind, 52-wk study of lumiracoxib 400 mg once daily (two to four times the recommended dose for osteoarthritis) vs. naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with osteoarthritis. Randomization was stratified for low-dose aspirin use and age (≤ 64, 65-74, ≥ 75 yr). The study was powered to investigate upper gastrointestinal ulcer complications (primary endpoint) in patients not taking aspirin and in the overall study population; other endpoints included cardiovascular, renal and hepatic measures. Conclusions: Therapeutic Arthritis Research and Gastrointestinal Event Trial was designed to provide definitive answers concerning the gastrointestinal safety of lumiracoxib, addressing the controversial issues arising from outcomes studies with other cyclooxygenase-2 selective inhibitors.

IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic arthritis research and gastrointestinal event trial of lumiracoxib)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 100 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 101 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:647392 CAPLUS
DOCUMENT NUMBER: 141:288911
TITLE: Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control
AUTHOR(S): Chen, L.-C.; Elliott, R. A.; Ashcroft, D. M.
CORPORATE SOURCE: School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK
SOURCE: Journal of Clinical Pharmacy and Therapeutics (2004), 29(3), 215-229
CODEN: JCPTED; ISSN: 0269-4727
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: To evaluate the relative analgesic efficacy and tolerability of single-dose COX-2 inhibitors in post-operative pain management. Method: Systematic review of randomized controlled trials (RCTs). Outcome measures: The area under the pain relief vs. time curve was used to evaluate the proportion of patient achieving at least 50% pain relief using validated equations. The proportions of patients experiencing any adverse event or specific adverse events were also examined Results: In all, 18 RCTs were included which contained 2783 patients. The results of the effects of single-dose analgesics on the basis of 50% of patients achieving pain relief over 6 h from dental pain models suggested that oral rofecoxib 50 mg was more effective than codeine/paracetamol 60/600 mg, and the rate ratio (RR) was 2.11 (95% CI 1.6-2.75). Valdecoxib 40 mg was also more effective than oxycodone/paracetamol 10/1000 mg (RR 1.34; 95% CI 1.11-1.62). There was no significant differences between other oral COX-2 inhibitors and non-selective non-steroidal antiinflammatory drugs (NSAIDs), except that celecoxib 200 mg was less effective than ibuprofen 400 mg (RR 0.66; 95% CI 0.48-0.90) and rofecoxib 50 mg (RR 0.65; 95% CI 0.49-0.87). The results from orthopedic pain model showed no significant difference between rofecoxib 50 mg and naproxen sodium 550 mg (RR 1.04; 95% CI 0.73-1.49). The adverse effects of single-dose COX-2 inhibitor used in short-term post-operative pain management were generally mild and less than non-selective NSAIDs, although there was no significant difference. Conclusions: The analgesic efficacy and tolerability of single-dose COX-2 inhibitors were more effective than opioid-containing analgesics and similar to non-selective NSAIDs in post-operative pain management. Further studies are needed to examine the efficacy and tolerability of COX-2 inhibitors compared against active comparators over a longer duration to assess whether these short-term effects are mirrored by longer-term outcomes and to determine their ultimate risk-benefit profile.

IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 101 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 102 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:640455 CAPLUS
DOCUMENT NUMBER: 142:68301
TITLE: The second generation of cyclooxygenase-2 specific inhibitors
AUTHOR(S): An, Fu-Rong; Cao, Hui-Ming
CORPORATE SOURCE: Department of Pharmacy, Renji Hospital Affiliated to Shanghai Second Medical University, Shanghai, 200001, Peop. Rep. China
SOURCE: Yaoxue Fuwu Yu Yanjiu (2004), 4(2), 173-177
CODEN: YFYYAH; ISSN: 1671-2838
PUBLISHER: Yaoxue Fuwu Yu Yanjiu Zazhishe
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Chinese
AB A review. The second generation of COX-2 specific inhibitors with high cyclooxygenase-2 (COX-2) selectivity was developed with the promise of further reduction of NSAID-typical adverse effects. The leading compds. are valdecoxib, parecoxib, etoricoxib and lumiracoxib. They have been proven to have efficacy in the treatment of pain and inflammation. Parecoxib as the first parenteral drug of NSAIDs has the potential to become the drug of choice for treatment of postoperative pain. In this article, the experiences of clin. use of valdecoxib, parecoxib, etoricoxib and lumiracoxib are reviewed.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(second generation of cyclooxygenase-2 specific inhibitors)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 103 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:640249 CAPLUS
DOCUMENT NUMBER: 141:253362
TITLE: Lumiracoxib (Prexige): a new selective cox-2 inhibitor
AUTHOR(S): Mysler, E.
CORPORATE SOURCE: OMI, Buenos Aires, Argent.
SOURCE: International Journal of Clinical Practice (2004), 58(6), 606-611
CODEN: IJCPF9; ISSN: 1368-5031
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Lumiracoxib, a new selective COX-2 inhibitor, has been recently approved in England and Mexico for the treatment of acute and chronic pain. Although it is the fifth COX-2 inhibitor to come to the market, it has a unique structure that could prove to be important in the adverse event profile. Double blind randomized trials have proved its efficacy in acute pain, dysmenorrhea, rheumatoid arthritis and osteoarthritis. Its gastrointestinal safety profile has been studied in multiple trials. The main clin. trail, therapeutic arthritis research and gastrointestinal event trial, has as primary end point: perforations, obstructions and bleeding and as secondary end points: cardiovascular, renal and hepatic safety profile. The results of this trial will probably change the way we look at selective COX-2 inhibitors.
IT 220991-20-8, Prexige
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Lumiracoxib; lumiracoxib as selective cox-2 inhibitor)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 104 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:589414 CAPLUS
DOCUMENT NUMBER: 141:134107
TITLE: A method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
INVENTOR(S): Arneric, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060366	A1	20040722	WO 2003-US38751	20031206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004235925	A1	20041125	US 2003-727717	20031204
PRIORITY APPLN. INFO.:			US 2002-433790P	P 20021217

OTHER SOURCE(S): MARPAT 141:134107
AB A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation or an inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of duloxetine, venlafaxine or atomoxetine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a CNS disorder, pain and inflammation, or inflammation-associated disorder suppressing treatment, prevention, or inhibition effective amount of the composition Compns. and pharmaceutical compns. that contain duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor are also disclosed.
IT 220991-20-8, COX189 220991-33-3, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment, prevention, or inhibition of CNS disorder and/or pain and inflammation using combination of duloxetine, venlafaxine or atomoxetine and cyclooxygenase-2 inhibitor)

L3 ANSWER 104 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 105 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:589409 CAPLUS
DOCUMENT NUMBER: 141:117197
TITLE: Compositions and a method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor
INVENTOR(S): Arneric, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060361	A2	20040722	WO 2003-US38770	20031205
WO 2004060361	A3	20040902		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004204411	A1	20041014	US 2003-727918	20031204
PRIORITY APPLN. INFO.:			US 2002-433780P	P 20021217

OTHER SOURCE(S): MARPAT 141:117197
AB A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition provides administering to the subject a combination of reboxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Pharmaceutical compns. containing reboxetine and a cyclooxygenase-2 selective inhibitor are also disclosed. For example, a combination of reboxetine and celebrex provided an effective anti-inflammatory activity in a rat carrageenan foot pad edema test, an effective analgesic activity in a rat carrageenan-induced analgesia test, and it was an efficacious treatment for collagen-induced arthritis in mice.
IT 220991-20-8, COX 189
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of reboxetine and cyclooxygenase-2 inhibitor for prevention and treatment of CNS disorder, pain and inflammation)
RN 220991-20-8 CAPLUS

L3 ANSWER 105 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 106 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:571761 CAPLUS
DOCUMENT NUMBER: 141:98912
TITLE: The second generation of COX-2 inhibitors: Clinical pharmacological point of view
AUTHOR(S): Stichtenoth, D. O.
CORPORATE SOURCE: Institute of Clinical Pharmacology, Medizinische Hochschule Hannover, Hannover, 30623, Germany
SOURCE: Mini-Reviews in Medicinal Chemistry (2004), 4(6), 617-624
CODEN: MMCIAE; ISSN: 1389-5575
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. In comparison to the first generation, they show an at least equivalent efficacy in the treatment of pain and inflammation. However, the postulated gain of safety is yet difficult to determine and seems to be, if any, small.
IT 220991-20-8, Prexige
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(second generation of COX-2 inhibitors)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 107 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:565129 CAPLUS
DOCUMENT NUMBER: 141:99705
TITLE: Methods and compositions using cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
INVENTOR(S): Stephenson, Diane T.; Taylor, Duncan P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058354	A1	20040715	WO 2003-US40955	20031222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004171664	A1	20040902	US 2003-743485	20031222
PRIORITY APPLN. INFO.:			US 2002-435078P	P 20021220

OTHER SOURCE(S): MARPAT 141:99705
AB The invention provides compns. and methods for the treatment of a vaso-occlusive event. More particularly, the invention provides a combination therapy for the treatment of a vaso-occlusive event comprising the administration to a subject of a selective serotonin reuptake inhibitor in combination with a cyclooxygenase-2 selective inhibitor.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 selective inhibitors and selective serotonin reuptake inhibitors for treatment or prevention of vaso-occlusive event)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 107 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 108 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:558187 CAPLUS
DOCUMENT NUMBER: 141:150673
TITLE: Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
AUTHOR(S): Kivitz, A. J.; Nayiager, S.; Schimansky, T.; Gimona, A.; Thurston, H. J.; Hawkeye, C.
CORPORATE SOURCE: Altoona Center for Clinical Research, Duncansville, PA, USA
SOURCE: Alimentary Pharmacology and Therapeutics (2004), 19(11), 1189-1198
CODEN: APTHEN; ISSN: 0269-2813
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase-2 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti-inflammatory drugs, in patients with osteoarthritis. Aim: To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis. Methods: A total of 893 patients with rheumatoid arthritis were randomized to lumiracoxib 400 mg once daily, lumiracoxib 800 mg once daily, ibuprofen 800 mg three times daily or celecoxib 200 mg twice daily for 13 wk, in a double-blind randomised controlled clin. trial. The primary endpoint was the cumulative incidence of gastroduodenal ulcers over 13 wk. Results: The incidence of gastroduodenal ulcers ≥3 mm with lumiracoxib 400 mg once daily (2.8%) or lumiracoxib 800 mg once daily (4.3%) was significantly lower than with ibuprofen (13.6%, all P < 0.01) and not different from celecoxib (1.9%). The incidence of adverse events was similar for lumiracoxib 400, 800 mg and celecoxib (78, 75 and 77%, resp.) and higher with ibuprofen (86%). Discontinuation for adverse events was highest for ibuprofen (12.5% vs. 7.9-8.8% for the other groups). Conclusions: Lumiracoxib demonstrated gastroduodenal safety superior to ibuprofen and similar to celecoxib in patients with rheumatoid arthritis.
IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 108 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 109 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:550871 CAPLUS
DOCUMENT NUMBER: 141:82300
TITLE: Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
INVENTOR(S): Maziasz, Timothy
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056349	A2	20040708	WO 2003-US40615	20031219
WO 2004056349	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004157848	A1	20040812	US 2003-742400	20031219
PRIORITY APPLN. INFO.:			US 2002-435392P	P 20021219

OTHER SOURCE(S): MARPAT 141:82300
AB The present invention provides compns. and methods for the treatment of herpes virus infections. In one aspect, the invention provides a combination therapy for treating a herpes virus infection comprising the administration to a subject of an anti-herpes virus agent in combination with a cyclooxygenase-2 selective inhibitor. In another aspect, the invention provides a mono therapy for treating a herpes virus infection comprising administering a cyclooxygenase-2 selective inhibitor to a subject.
IT 220991-20-8, Lumiracoxib 220991-33-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 selective inhibitors optionally in combination with other antiviral agents for treatment of herpesvirus infections)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 109 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 110 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:535023 CAPLUS
DOCUMENT NUMBER: 141:235999
TITLE: Pharmacokinetics of lumiracoxib in plasma and synovial fluid
AUTHOR(S): Scott, Graham; Rordorf, Christiane; Reynolds, Christine; Kalbag, Jyoti; Looby, Michael; Milosavljev, Slavica; Weaver, Margaret; Huff, John P.; Ruff, Dennis A.
CORPORATE SOURCE: Novartis Pharmaceuticals, Horsham, UK
SOURCE: Clinical Pharmacokinetics (2004), 43(7), 467-478
CODEN: CPKNDH; ISSN: 0312-5963
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Lumiracoxib is a new cyclooxygenase-2 (COX-2) selective inhibitor in development for the treatment of rheumatoid arthritis, osteoarthritis and acute pain. The purpose of this study was to investigate the pharmacokinetics of lumiracoxib in plasma and knee joint synovial fluid from patients with rheumatoid arthritis. An open-label multiple-dose study was conducted evaluating the steady-state pharmacokinetics of lumiracoxib in plasma and synovial fluid after 7 days of treatment with lumiracoxib 400mg once daily. Males and females aged 18-75 yr with rheumatoid arthritis, having moderate to significant synovial fluid effusion of the knee. Following a 7-day washout period for previous nonsteroidal anti-inflammatory drugs, 22 patients (17 female, 5 male) received lumiracoxib 400mg once daily for seven consecutive days. On day 7, following an overnight fast, a final dose of lumiracoxib was administered and serial blood and synovial fluid samples were collected for up to 28 h. Lumiracoxib and its metabolites (4'-hydroxy-lumiracoxib and 5-carboxy-4'-hydroxy-lumiracoxib) were measured by validated high performance liquid chromatog.-mass spectrometry methods. The steady-state pharmacokinetics of lumiracoxib were evaluated in plasma and synovial fluid by both a population pharmacokinetic model and noncompartmental anal. Lumiracoxib was rapidly absorbed (peak plasma concentration at 2 h) and the terminal elimination half-life in plasma was short (6 h). Lumiracoxib concns. were initially higher in plasma than in synovial fluid; however, from 5 h after administration until the end of the 28-h assessment period, concns. of lumiracoxib were higher in synovial fluid than in plasma. Peak drug concentration in synovial fluid occurred 3-4 h later than the peak plasma concentration The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 μg/L) was approx. three times higher than the mean value in plasma (155 μg/L), and the area under the concentration-time curve from 12 to 24 h after administration was 2.6-fold higher for synovial fluid than for plasma. Median lumiracoxib protein binding was similar in plasma and

L3 ANSWER 110 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
synovial fluid (range 97.9-98.3%). Concns. of 4'-hydroxy-lumiracoxib, the active COX-2 selective metabolite, remained low in comparison with parent drug in both plasma and synovial fluid. The concn. of lumiracoxib in synovial fluid at 24 h after administration would be expected to result in substantial inhibition of prostaglandin E2 formation. The kinetics of distribution of lumiracoxib in synovial fluid are likely to extend the therapeutic action of the drug beyond that expected from plasma pharmacokinetics. These data support the use of lumiracoxib in a once-daily regimen for the treatment of rheumatoid arthritis.
IT 220991-37-7, 4'-Hydroxy-lumiracoxib
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pharmacokinetics of lumiracoxib in plasma and synovial fluid)
RN 220991-37-7 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluoro-4-hydroxyphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



IT 220991-20-8, Lumiracoxib
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetics of lumiracoxib in plasma and synovial fluid)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 190-196

L3 ANSWER 190 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:754159 CAPLUS
DOCUMENT NUMBER: 137:263297
TITLE: Preparation of 2,7-diamino-5-heptenoic acid derivatives for the treatment of cancer
INVENTOR(S): Manning, Pamela T.; Connor, Jane R.; Seibert, Karen; Rao, Chinthalapally V.; Reddy, Bandaru S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 295 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076395	A2	20021003	WO 2002-US8938	20020321
WO 2002076395	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003013702	A1	20030116	US 2001-961969	20010924
CA 2441394	AA	20021003	CA 2002-2441394	20020321
EP 1463495	A2	20041006	EP 2002-717708	20020321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500259	T2	20050106	JP 2002-574911	20020321

PRIORITY APPLN. INFO.:
US 2001-278512P P 20010323
US 2001-961969 A 20010924
WO 2002-US8938 W 20020321

OTHER SOURCE(S): MARPAT 137:263297

AB Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cyclooxygenase-2 in a pharmaceutical composition 2,7-Diamino-5-heptenoic acid derivs. R7N:CMeNHCH2CR1:CR2CH2CH2CH(NH2)C(O)J [R1, R2 = H, halo, alkyl, haloalkyl (at least one of R1 or R2 contains halogen); R7 = H, OH; J = OH, alkoxy, NR3R4, where R3 = H, alkyl, alkenyl, alkynyl and R4 = H, (un)substituted heterocyclyl] or their pharmaceutically-acceptable salts are among the compds. claimed. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride was prepared by a multistep procedure starting from L-glutamic acid and showed IC50 values 0.36, 68, 3.6, and 0.1 μM in hiNOS, hecNOS, hncNOS, and human cartilage assays, resp.

L3 ANSWER 190 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 220991-20-8, COX 189
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of diaminoheptenoic acid derivs. for treatment of cancer)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 191 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:184950 CAPLUS
DOCUMENT NUMBER: 136:236859
TITLE: Pharmaceutical compositions for treating a cyclooxygenase-2 dependent disorder or condition comprising 5-methyl-2-(2-chloro-6-fluoroanilino)phenylacetic acid
INVENTOR(S): Bateman, Simon David; Gimona, Alberto; Holinej, Jurij; Huels, Jasper; Jayawardene, Sumedha; Karabelas, Argeris Jerry; Khaled, Maha Y.; Karnachi, Anees Abdulquadar; Nic Lochlainn, Eimear Mairin; Macerata, Richard; Sloan, Victor
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020090	A2	20020314	WO 2001-EP10448	20010910
WO 2002020090	A3	20030530		
WO 2002020090	C2	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2416771	AA	20020314	CA 2001-2416771	20010910
AU 2002013900	A5	20020322	AU 2002-13900	20010910
BR 2001013809	A	20030729	BR 2001-13809	20010910
EP 1331972	A2	20030806	EP 2001-982270	20010910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527458	T2	20040909	JP 2002-524572	20010910
US 2002061932	A1	20020523	US 2001-950538	20010911
ZA 2003000555	A	20040331	ZA 2003-555	20030121
NO 2003001095	A	20030310	NO 2003-1095	20030310
US 2004186179	A1	20040923	US 2004-807734	20040324

PRIORITY APPLN. INFO.:
US 2000-231655P P 20000911
US 2000-232261P P 20000914
WO 2001-EP10448 W 20010910
US 2001-950538 A1 20010911

GI

L3 ANSWER 191 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB A composition for treating a cyclooxygenase-2 dependent disorder or condition comprises the title compound (I) or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 h.
IT 220991-20-8
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treating a cyclooxygenase-2 dependent disorder or condition comprising 5-methyl-2-(2-chloro-6-fluoroanilino)phenylacetic acid)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 192 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:581708 CAPLUS
DOCUMENT NUMBER: 135:147440
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors as gastroprokinetic agents
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
PATENT ASSIGNEE(S): GlaxoSmithKline, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056573	A1	20010809	WO 2001-GB423	20010201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001030395	A5	20010814	AU 2001-30395	20010201
EP 1259239	A2	20021127	EP 2001-902541	20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003521516	T2	20030715	JP 2001-556472	20010201
US 2003022897	A1	20030130	US 2002-182080	20020725
US 6759413	B2	20040706		
US 2004192694	A1	20040930	US 2004-786423	20040225
PRIORITY APPLN. INFO.:			GB 2000-2336 A	20000201
			WO 2001-GB423 W	20010201
			US 2002-182080 A1	20020725

AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of a disorder ameliorated by a gastroprokinetic agent.
IT 220991-20-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(COX 189; cyclooxygenase-2 inhibitors as gastroprokinetic agents)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 192 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 220991-20-8D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(cyclooxygenase-2 inhibitors as gastroprokinetic agents)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 193 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:581693 CAPLUS
DOCUMENT NUMBER: 135:147439
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors for constipation
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056555	A2	20010809	WO 2001-GB416	20010201
WO 2001056555	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1251839	A2	20021030	EP 2001-948935	20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003521511	T2	20030715	JP 2001-556247	20010201
US 2003013717	A1	20030116	US 2002-182169	20020725
PRIORITY APPLN. INFO.:			GB 2000-2312 A	20000201
			WO 2001-GB416 W	20010201

AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of constipation.
IT 220991-20-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(COX 189; cyclooxygenase-2 inhibitors for treatment of constipation)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



IT 220991-20-8D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L3 ANSWER 193 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(cyclooxygenase-2 inhibitors for treatment of constipation)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 194 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472471 CAPLUS
DOCUMENT NUMBER: 135:81971
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045683	A2	20010628	WO 2000-GB4883	20001219
WO 2001045683	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1239879	A2	20020918	EP 2000-985627	20001219
EP 1239879	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519104	T2	20030617	JP 2001-546422	20001219
AT 260119	E	20040315	AT 2000-985627	20001219
US 2003004128	A1	20030102	US 2002-168195	20020618

PRIORITY APPLN. INFO.: GB 1999-30075 A 19991220
WO 2000-GB4883 W 20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and an NSAID, e.g., a COX-2 inhibitor. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol (I) was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection. I and 2-(4-ethoxy-phenyl)-3-(4-methanesulfonylphenyl)pyrazolo[1,5-b]pyridazine(COX-2 inhibitor), were administered at 1% to rats. The compds. showed inhibition of

L3 ANSWER 194 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
carrageenan-induced edema and allodynia.
IT 220991-20-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX 189; formulations of adenosine A1 agonists)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:247306 CAPLUS
DOCUMENT NUMBER: 134:280604
TITLE: Preparation of phenylacetic acid derivatives as inhibitors of cyclooxygenase(II)
INVENTOR(S): Acemoglu, Murat; Allmendinger, Thomas; Calienni, John Vincent; Cercus, Jacques; Loiseleur, Olivier; Sedelmeier, Gottfried; Xu, David
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023346	A2	20010405	WO 2000-EP9346	20000925
WO 2001023346	A3	20020110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379553	AA	20010405	CA 2000-2379553	20000925
TR 200200745	T2	20020621	TR 2002-200200745	20000925
EP 1216226	A2	20020626	EP 2000-969292	20000925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014314	A	20021112	BR 2000-14314	20000925
JP 2003510303	T2	20030318	JP 2001-526501	20000925
NZ 517461	A	20031031	NZ 2000-517461	20000925
AU 775416	B2	20040729	AU 2000-79067	20000925
NO 2002001368	A	20020527	NO 2002-1368	20020319
ZA 2002002367	A	20021121	ZA 2002-2367	20020325

PRIORITY APPLN. INFO.: GB 1999-22830 A 19990927
WO 2000-EP9346 W 20000925

OTHER SOURCE(S): MARPAT 134:280604
GI

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Phenylacetic acid derivs. I [R = Me, Et; R1 = Cl, F, R2 = H, F; R3 = H, F, Cl, Me, Et, MeO, EtO, OH; R4 = H, F; R5 = Cl, F, CF3, Me] were prepared by cleaving lactams II. E.g, 5-methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid was prepared by cleaving N-(2',6'-dichloro-4'-methylphenyl)-5-methyloxindole (preparation given). I are selective inhibitors of cyclooxygenase(II).
IT 220991-15-1P 220991-16-2P 220991-17-3P
220991-18-4P 220991-19-5P 220991-20-8P
220991-21-9P 220991-22-0P 220991-23-1P
220991-24-2P 220991-25-3P 220991-26-4P
220991-27-5P 220991-28-6P 220991-29-7P
220991-30-0P 220991-31-1P 220991-33-3P
220991-34-4P 220991-35-5P 220991-36-6P
220991-37-7P 220991-48-0P 220991-63-9P
332903-31-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylacetic acid derivs. as inhibitors of cyclooxygenase(II))
RN 220991-15-1 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)



RN 220991-16-2 CAPLUS
CN Benzeneacetic acid, 5-methyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-17-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-18-4 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 220991-19-5 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 220991-24-2 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)



RN 220991-25-3 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4-fluoro-6-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-26-4 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-ethyl- (9CI) (CA
INDEX NAME)



RN 220991-27-5 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA
INDEX NAME)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-21-9 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichloro-4-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)



RN 220991-22-0 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-23-1 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-methyl- (9CI)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-28-6 CAPLUS
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,6-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 220991-29-7 CAPLUS
CN Benzeneacetic acid,
2-[(4-ethoxy-2,3,5,6-tetrafluorophenyl)amino]-5-ethyl-
(9CI) (CA INDEX NAME)



RN 220991-30-0 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-ethyl- (9CI)
(CA INDEX NAME)



RN 220991-31-1 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-ethyl- (9CI)
(CA INDEX NAME)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-34-4 CAPLUS
CN Benzeneacetic acid, 2-[(4-chloro-2-fluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-35-5 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-difluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-36-6 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4-fluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-37-7 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluoro-4-hydroxyphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-48-0 CAPLUS
CN Benzeneacetic acid, 2-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-63-9 CAPLUS
CN Benzeneacetic acid, 2-[[2-fluoro-6-(trifluoromethyl)phenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 332903-31-8 CAPLUS
CN Benzeneacetic acid, 5-methyl-2-[(2,3,4,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:184221 CAPLUS
DOCUMENT NUMBER: 130:209502
TITLE: Preparation of 5-alkyl-2-arylaminophenylacetic acids as COX-2 cyclooxygenase inhibitors
INVENTOR(S): Fujimoto, Roger Aki; Mcquire, Leslie Wighton; Mugrage, Benjamin Biro; Van Duzer, John Henry; Xu, Daqiang
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis-Erfindungen Verwaltungs-Gesellschaft m.b.H.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911605	A1	19990311	WO 1998-EP5414	19980826
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6291523	B1	20010918	US 1998-139254	19980825
CA 2298033	AA	19990311	CA 1998-2298033	19980826
AU 9895340	A1	19990322	AU 1998-95340	19980826
AU 743371	B2	20020124		
EP 1007505	A1	20000614	EP 1998-948872	19980826
EP 1007505	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
TR 200000447	T2	20000721	TR 2000-200000447	19980826
BR 9812010	A	20001212	BR 1998-12010	19980826
JP 2001514244	T2	20010911	JP 2000-508646	19980826
NZ 502669	A	20020201	NZ 1998-502669	19980826
RU 2186762	C2	20020810	RU 2000-107121	19980826
AT 237580	E	20030515	AT 1998-948872	19980826
PT 1007505	T	20030829	PT 1998-948872	19980826
ES 2197508	T3	20040101	ES 1998-948872	19980826
SK 283773	B6	20040108	SK 2000-247	19980826
ZA 9807785	A	19990301	ZA 1998-7785	19980827
MX 200001585	A	20001020	MX 2000-1585	20000215
NO 2000000943	A	20000225	NO 2000-943	20000225
US 6310099	B1	20011030	US 2000-722767	20001127
HK 1031374	A1	20041224	HK 2001-102175	20010326
US 2002013369	A1	20020131	US 2001-950957	20010913
US 6451858	B2	20020917		
US 2002183391	A1	20021205	US 2002-201336	20020723
US 6727281	B2	20040427		
US 2004122254	A1	20040624	US 2003-728244	20031204
PRIORITY APPLN. INFO.:			US 1997-57803P	P 19970828
			US 1997-69837P	P 19970828
			US 1998-139254	A1 19980825

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

WO 1998-EP5414	W	19980826
US 2000-722767	A1	20001127
US 2001-950957	A1	20010913
US 2002-201336	A1	20020723

OTHER SOURCE(S): MARPAT 130:209502
GI



I

AB The title compds. I [R = Me, Et; R1 = chloro, fluoro; R2 = hydrogen, fluoro; R3 = hydrogen, fluoro, chloro, Me, Et, methoxy, ethoxy, hydroxy; R4 = hydrogen, fluoro; R5 = chloro, fluoro, trifluoromethyl, methyl], selective COX-2 cyclooxygenase inhibitors, were prepared IC50 values for I in the COX-2 inhibition assay are as low as 0.005 μM, whereas IC50 values in the COX-1 inhibition assay are > 30 μM. E.g., 5-methyl-2-(2,4-dichloro-6-trifluoromethylanilino)phenylacetic acid was prepared

IT 220991-15-1P 220991-16-2P 220991-17-3P
220991-18-4P 220991-19-5P 220991-20-8P
220991-21-9P 220991-22-0P 220991-23-1P
220991-24-2P 220991-25-3P 220991-26-4P
220991-27-5P 220991-28-6P 220991-29-7P
220991-30-0P 220991-31-1P 220991-32-2P
220991-33-3P 220991-34-4P 220991-35-5P
220991-36-6P 220991-37-7P 220991-48-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkyl(arylamino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

RN 220991-15-1 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 220991-19-5 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-21-9 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichloro-4-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)



RN 220991-22-0 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-23-1 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-methyl- (9CI)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-16-2 CAPLUS
CN Benzeneacetic acid, 5-methyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 220991-17-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-18-4 CAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monopotassium salt (9CI) (CA INDEX NAME)



● K

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 220991-24-2 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)



RN 220991-25-3 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4-fluoro-6-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-26-4 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-27-5 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-28-6 CAPLUS
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,6-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 220991-29-7 CAPLUS
CN Benzeneacetic acid, 2-[(4-ethoxy-2,3,5,6-tetrafluorophenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-30-0 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-31-1 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-36-6 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4-fluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-37-7 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluoro-4-hydroxyphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-48-0 CAPLUS
CN Benzeneacetic acid, 2-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



IT 220991-60-6P 220991-63-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkyl(arylamino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

RN 220991-60-6 CAPLUS
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]-, monosodium salt (9CI) (CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-32-2 CAPLUS
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-34-4 CAPLUS
CN Benzeneacetic acid, 2-[(4-chloro-2-fluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-35-5 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-difluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 220991-63-9 CAPLUS
CN Benzeneacetic acid, 2-[[2-fluoro-6-(trifluoromethyl)phenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 170-180

L3 ANSWER 170 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:492716 CAPLUS
DOCUMENT NUMBER: 139:63316
TITLE: Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
INVENTOR(S): Masferrer, Jaime L.; Cherrington, Julie M.; Leahy, Kathleen M.; Zweifel, Ben S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of Appl. No. PCT/US99/30693.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 21
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119895	A1	20030626	US 2002-150546	20020516
WO 2000038730	A2	20000706	WO 1999-US30693	19991222
WO 2000038730	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1522313	A1	20050413	EP 2004-26577	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
CA 2484324	AA	20031127	CA 2003-2484324	20030515
WO 2003097044	A1	20031127	WO 2003-US15582	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2003010027	A	20050215	BR 2003-10027	20030515
EP 1509224	A1	20050302	EP 2003-734058	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 1998-113786P P 19981223
WO 1999-US30693 A2 19991222
US 1999-385214 A 19990827

L3 ANSWER 170 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 170 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

EP 1999-968939 A3 19991222
US 2002-150546 A 20020516
WO 2003-US15582 W 20030515

OTHER SOURCE(S): MARPAT 139:63316
AB The invention provides methods and compns. useful for treatment or prevention of neoplasia by administering a combination comprising a 3-heteroaryl-2-indolinone compound (preparation included) and a COX-2 selective inhibitor. Further provided are compns., pharmaceutical compns., and kits for treatment and prevention of neoplasia.
IT 220991-20-8, COX189 220991-20-8D, COX189, prodrug deriva. 220991-33-3 220991-33-3D, prodrug deriva.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heteroaryl indolinone-cyclooxygenase 2 inhibitor combination for treatment of neoplasia)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 171 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:472372 CAPLUS
DOCUMENT NUMBER: 139:41825
TITLE: Combination therapy comprising a cyclooxygenase-2 inhibitor
INVENTOR(S): Murray, Richard K.; Yates, John
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049720	A1	20030619	WO 2002-US38376	20021203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-338341P P 20011207

AB The present invention encompasses a method and kit for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in humans in need of such treatment. The method consists of orally administering to the patient a cyclooxygenase-2 selective inhibitor on a once or twice daily basis in an amount effective to treat the disease or condition and orally administering to the patient aspirin once every 2-7 days in an amount effective to reduce the risk of the thrombotic cardiovascular event, while maintaining a high level of upper gastrointestinal safety and tolerability.
IT 220991-20-8, COX-189
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy comprising cyclooxygenase-2 inhibitor)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 171 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 172 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:376685 CAPLUS
DOCUMENT NUMBER: 138:362661
TITLE: Cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies
INVENTOR(S): Chen, Ying-Nan Pan; Lassota, Peter; Wood, Alexander Wallace
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039599	A1	20030515	WO 2002-EP12343	20021105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2461373	AA	20030515	CA 2002-2461373	20021105
EP 1443967	A1	20040811	EP 2002-787572	20021105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013932	A	20040831	BR 2002-13932	20021105
JP 2005510517	T2	20050421	JP 2003-541889	20021105
US 2005032899	A1	20050210	US 2004-494221	20040915

PRIORITY APPLN. INFO.: US 2001-333016P P 20011106
US 2002-419314P P 20021017
WO 2002-EP12343 W 20021105

OTHER SOURCE(S): MARPAT 138:362661

AB The invention provides a combination which comprises (a) a cyclooxygenase-2 inhibitor and (b) a histone deacetylase inhibitor for simultaneous, concurrent, sep., or sequential use, especially for use in the treatment of premalignant colon lesions or colon cancer or other malignancies in a mammal, particularly a human. The invention also provides pharmaceutical compns. comprising such a combination and a method of treating premalignant colon lesions (e.g.polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human, with such a combination. The invention further provides a com. package or product comprising such a combination.

IT 220991-20-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies)

RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



IT 523978-20-3 523978-21-4 523978-22-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies)

RN 523978-20-3 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, mixt. with (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (9CI) (CA INDEX NAME)

CM 1

CRN 404951-53-7
CMF C22 H25 N3 O3

Double bond geometry as shown.



CM 2

CRN 220991-20-8
CMF C15 H13 Cl F N O2



RN 523978-21-4 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, mixt. with (2E)-N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (9CI) (CA INDEX NAME)

CM 1

CRN 404951-52-6
CMF C20 H21 N3 O2

Double bond geometry as shown.



CM 2

CRN 220991-20-8
CMF C15 H13 Cl F N O2



RN 523978-22-5 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, mixt. with (2E)-N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (9CI) (CA INDEX NAME)

CM 1

CRN 404950-80-7
CMF C21 H23 N3 O2

L3 ANSWER 172 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



CM 2

CRN 220991-20-8
CMF C15 H13 Cl F N O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 173 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 173 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:376635 CAPLUS
DOCUMENT NUMBER: 138:362717
TITLE: Combination therapy for treating Alzheimer's disease with HMG-CoA reductase inhibitors and COX-2 inhibitors
INVENTOR(S): MacNeil, Douglas J.; Rosenblum, Charles I.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039542	A1	20030515	WO 2002-US32790	20021011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-330158P	P 20011017

AB The instant invention provides a drug combination comprised of an HMG-CoA reductase inhibitor in combination with a COX-2 inhibitor, which is useful for treating or preventing Alzheimer's disease.
IT 220991-20-8, COX 189
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Alzheimer's disease treatment with combination of HMG-CoA reductase and COX-2 inhibitors)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 174 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:334916 CAPLUS
DOCUMENT NUMBER: 138:343907
TITLE: Pharmaceutical composition for the treatment of malignancies comprising in combination a bisphosphonate, a COX-2 inhibitor and a taxol
INVENTOR(S): Lipton, Allan; Witters, Lois Mary; Green, Jonathan
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035081	A1	20030501	WO 2002-EP11696	20021018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2461085	AA	20030501	CA 2002-2461085	20021018
EP 1443942	A1	20040811	EP 2002-801899	20021018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013410	A	20041103	BR 2002-13410	20021018
JP 2005506371	T2	20050303	JP 2003-537648	20021018
US 2005014726	A1	20050120	US 2004-493042	20040823
PRIORITY APPLN. INFO.:			US 2001-345921P	P 20011019
			WO 2002-EP11696	W 20021018

OTHER SOURCE(S): MARPAT 138:343907
AB A pharmaceutical composition for treatment of malignancies, in particular a malignant disease which is associated with the development of bone metastases or excessive bone resorption, comprises in combination a bisphosphonates, COX-2 inhibitor and/or a taxol or derivative thereof for simultaneous, sequential or sep. use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonates, an effective amount of a COX-2 inhibitor and/or and effective amount of a taxol or derivative thereof. Pharmaceutical compns. are given for COX-2 inhibitors.
IT 220991-20-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for the treatment of malignancies comprising in combination a bisphosphonate, a COX-2 inhibitor and a taxol)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 174 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 175 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:334885 CAPLUS
DOCUMENT NUMBER: 138:343902
TITLE: Combinations comprising a selective cyclooxygenase-2 inhibitor for cancer treatment
INVENTOR(S): Chen, Ying-nan Pan; Lassota, Peter; Wood, Alexander Wallace
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035047	A2	20030501	WO 2002-EP11924	20021024
WO 2003035047	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2464309	AA	20030501	CA 2002-2464309	20021024
EP 1441714	A2	20040804	EP 2002-787507	20021024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005506366	T2	20050303	JP 2003-537614	20021024
BR 2002013486	A	20050510	BR 2002-13486	20021024
ZA 2004002939	A	20050207	ZA 2004-2939	20040416
US 2005043409	A1	20050224	US 2004-493297	20041008
PRIORITY APPLN. INFO.:			US 2001-344734P	P 20011025
			US 2001-344735P	P 20011025
			US 2001-336033P	P 20011115
			WO 2002-EP11924	W 20021024

OTHER SOURCE(S): MARPAT 138:343902
AB A combination therapy for treating patients suffering from pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, is disclosed. The patient is treated concurrently with a cyclooxygenase-2 inhibitor and at least one compound selected from the group consisting of a microtubule interfering agent, an epithelial growth factor receptor tyrosine protein kinase inhibitor and a vascular endothelial growth factor receptor tyrosine kinase inhibitor. 5-Methyl-2-(2'-chloro-6'-fluoro-anilino)phenylacetic acid (COX) and 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine (VEGFR) are teated as single agents and together as combination therapy in a mouse model of adenomatous polyposis for the

L3 ANSWER 175 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
prevention and treatment of intestinal polyps. VEGFR is administered to the mice orally at 100 mg/kg, 5 times a week for 3 wk and COX is administered in the feed mix at a concn. of 125 ppm. Both agents alone cause a statistically significant redn. in the no. of newly formed intestinal polyps. The combination further reduces the no. of new polyps to a level that is lower than either agent alone and that is statistically significant.
IT 220991-20-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising cyclooxygenase-2 inhibitor for cancer treatment)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 176 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:319725 CAPLUS
DOCUMENT NUMBER: 138:326598
TITLE: Combinations comprising COX-2 inhibitors and aspirin
INVENTOR(S): Gimona, Alberto
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033001	A1	20030424	WO 2002-EP11380	20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2458981	AA	20030424	CA 2002-2458981	20021010
EP 1435968	A1	20040714	EP 2002-779476	20021010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013181	A	20040831	BR 2002-13181	20021010
JP 2005505606	T2	20050224	JP 2003-535804	20021010
ZA 2004001302	A	20050104	ZA 2004-1302	20040218
US 2004235802	A1	20041125	US 2004-487759	20040224
PRIORITY APPLN. INFO.:			GB 2001-24459	A 20011011
			WO 2002-EP11380	W 20021010

OTHER SOURCE(S): MARPAT 138:326598
AB A pharmaceutical composition is provided for treatment of conditions in mammals which are responsive to COX-2 inhibition which comprises in combination a COX-2 inhibitor and low-dose aspirin for simultaneous, sequential or sep. use. Examples of wet granulated tablet compns. are given and clin. studies using COX 189 as the selective COX-2 inhibitor.
IT 220991-20-8, COX 189
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising COX-2 inhibitors and aspirin)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS

L3 ANSWER 176 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 177 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:287975 CAPLUS
DOCUMENT NUMBER: 139:285415
TITLE: Annual update 2003 musculoskeletal drugs
AUTHOR(S): Graul, A. I.; Revel, L.; Prous, J.
CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
SOURCE: Drugs of the Future (2003), 28(1), 69-108
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The Annual Update 2003 of Musculoskeletal Drugs is comprised of
a Compendium of drug R&D in the areas of musculoskeletal and connective tissue diseases, including 86 drugs for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma and Sjogren's syndrome, and Monograph Updates on the following
drugs that have been published in previous issues of the journal: abetimus
sodium, adalimumab, etoricoxib, iguratimod, licofelone, lumiracoxib, prasterone, tacrolimus and valdecoxib. The Annual Update also includes a comprehensive table listing the drugs, their manufacturers, indications and developmental phases.
IT 220991-20-8, Lumiracoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(annual update 2003 musculoskeletal drugs)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 178 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:202469 CAPLUS
DOCUMENT NUMBER: 138:215299
TITLE: Method for the treatment and prevention of cachexia by
using cyclooxygenase-2 selective inhibitors
INVENTOR(S): Muglia, Louis
PATENT ASSIGNEE(S): Washington University, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020268	A1	20030313	WO 2002-US27914	20020830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087942	A1	20030508	US 2002-231553	20020830
PRIORITY APPLN. INFO.:			US 2001-316004P	P 20010831

OTHER SOURCE(S): MARPAT 138:215299
AB Cachexia, including anorexia and other forms of weight loss, is a frequent
complication of acute and chronic infections, and result from induction of
cytokines, prostaglandins, and other inflammatory mediators that are critical
for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound
IT 220991-20-8, Lumiracoxib 220991-30-0 220991-32-2
220991-33-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment and prevention of cachexia by using cyclooxygenase-2 selective inhibitors)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 178 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 220991-30-0 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 220991-32-2 CAPLUS
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 220991-33-3 CAPLUS
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 179 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:202464 CAPLUS
DOCUMENT NUMBER: 138:210372
TITLE: Pharmaceutical compositions comprising lumiracoxib
INVENTOR(S): Karnachi, Anees Abdulquadar; Bateman, Simon David
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020261	A1	20030313	WO 2002-EP9701	20020830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2003114527	A1	20030619	US 2002-231438	20020829
CA 2456604	AA	20030313	CA 2002-2456604	20020830
EP 1425005	A1	20040609	EP 2002-767455	20020830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012155	A	20040713	BR 2002-12155	20020830
JP 2005520785	T2	20050714	JP 2003-524569	20020830
ZA 2004000877	A	20041101	ZA 2004-877	20040203
NO 2004000860	A	20040422	NO 2004-860	20040226
PRIORITY APPLN. INFO.:			US 2001-316389P P	20010831
			WO 2002-EP9701 W	20020830

AB Disclosed herein tablets and methods of treatment comprising the administration of such tablets. The tablets are immediate release tablets that comprise about 400 mg of lumiracoxib or a salt thereof, where the lumiracoxib or its salt thereof comprises 60-70% by weight of the tablet. The methods involve the administration of the tablets of the invention to individuals in need of administration of such tablets. Thus, an optimized formulation consisted of 3 parts: (1) a granulation composition comprised drug 65.04, AcDiSol 2.15, Povidone-K30 6.60, and water 18.12% (does not appear in the final product); (2) a blending formulation contained Avicel PH102 23.56,, AcDiSol 2.15, and Mg stearate 0.50%; a film coating comprised Opadry (Global White 00F18296) 84.44, Opadry (Global Red 00F15613) 13.90, Opadry (Global Black 00F17713) 1.51%, and water qs (does not appear in the final product).
IT 220991-20-8, Lumiracoxib

L3 ANSWER 180 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:158143 CAPLUS
DOCUMENT NUMBER: 138:313740
TITLE: Lumiracoxib Novartis
AUTHOR(S): Ding, Changhai; Jones, Graeme
CORPORATE SOURCE: Menzies Centre for Population Health Research, University of Tasmania, Tasmania, 7000, Australia
SOURCE: IDrugs (2002), 5(12), 1168-1172
CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late Dec. 2000, phase III trials had been initiated and were ongoing in Dec. 2001.
IT 220991-20-8, Lumiracoxib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lumiracoxib use as antiinflammatory, antibiotic and analgesic drug.)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 179 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising lumiracoxib)
RN 220991-20-8 CAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT